46 patients (0.63%) received salvage surgery out of 7,290 patients underwent surgery for primary lung cancer at Median follow-up time was 24.5 months (range, 2-157.6). Of 46 patients evaluated, 30 (65.2%) were men, the median age was 64.5 years (range, 20-78 years), 22 (47.8%) underwent chemotherapy, 18 (39.1%) underwent resection after definitive chemoradiotherapy, 3 (6.5%) underwent resection after SBRT and 3 (6.5%) underwent resection after PBT. The number of patients undergoing salvage surgery has increased in recent years: 9 patients were between 2000 and 2009, whereas 37 patients were between 2010 and 2018. Method of surgical resection was as follows: 28 lobectomies (2 bilobectomy, 15 right upper, 1 right middle, 6 right lower, 2 left upper, 2 left lower), 10 pneumonectomies (left:right¼7:3). One patient received a wedge resection, and one recieved wedge resection with chest well resection, and 2 segmentectomy and lymphadectomy for residual lymph nodes respectively. A complete resection (R0) was achieved in 42 cases (91.3%). Postoperative complications were observed in 3 patients (6.5%): prolonged air leakage, bronchopleural fistula, and atrial fibrillation. There were no post-operative deaths within 30 days after surgery. The five-year progression free and overall survival rate after surgical resection was 39.1% (95% CI.: 19.9-57.9) and 64.1% (95% CI.: 39.3-80.9), respectively. Conclusion: The frequency of salvage surgery after initial treatment has been increasing possibly due to a better treatment course using novel medical and radiation oncology technique. Salvage pulmonary resections demonstrated acceptable morbidity and mortality with promising long-term efficacy in selected patients.
Background: To pursue personalized cancer care, it is important to determine tumor response during treatment and associate these with outcomes. Previously published literature reported that adenocarcinoma and squamous cell carcinoma have different treatment response and outcome. Therefore, the aim of this study is to examine the prognostic value of volumetric changes of the primary tumor measured on Cone Beam-CT (CBCT) during radiotherapy for locally advanced NSCLC patients treated with concurrent chemoradiation (CCRT). Method: 394 NSCLC-patients treated with CCRT between 2007-2013 were included. To determine GTV during treatment, deformable image registration of the planning-CT to all CBCTs was performed. To assess the association of volumetric changes of the gross tumor volume (GTV) with overall survival (OS), progression free survival (PFS) and local regional control (LRC), multivariate cox regression analyses were performed, accounting for potential confounders. Furthermore, the entire group was stratified based on adenocarcinoma and non-adenocarcinoma and an additional log rank and multivariate cox regression analysis based on pathology was performed. Result: In patients with adenocarcinoma, GTV reduction during CCRT was significantly associated with worse OS (HR¼1.55, Figure 1 ). GTV reduction was not significantly associated with PFS and LRC in either subgroup. For the entire group no significant association was found between GTV volume change and OS, PFS or LRC. Conclusion: Surprisingly, no associations between GTV changes and outcomes were found for the entire treatment group. In patients with adenocarcinoma, GTV changes during concurrent chemoradiaton measured on CBCT were a significant predictor for OS. Background: Radiation with platinum-based doublet chemotherapy is the standard of care for patients with unresectable stage III nonsmall-cell lung cancer (NSCLC). Despite aggressive treatment, progression-free survival and overall survival remain poor. It is unclear whether any tumor genetic alterations are associated with response to therapy. Method: We retrospectively reviewed clinical outcomes of patients with stage III NSCLC treated with definitive radiation, who had undergone tumor molecular profiling through an institutional next-generation sequencing platform. This platform is an FDAapproved, targeted-DNA-sequencing panel that contains 341 (now expanded to 468) somatic mutations and other genetic alterations. Basic patient and tumor characteristics, clinical outcomes including loco-regional recurrence, distant recurrence, and overall survival, were collected. Overall and recurrence-free survivals were estimated using the Kaplan-Meier method. Cox proportional hazards model was used to investigate association between clinical outcome and genetic alterations. Result: We identified 110 patients with stage III NSCLC who were treated with definitive radiation between 2013 and 2017 and underwent tumor molecular profiling. Fifty-one patients (46%) had stage IIIA disease and 59 patients (54%) had stage IIIB disease. Median radiation dose delivered was 60Gy in 30 fractions (range 48.6Gy to 74Gy). Either concurrent or sequential chemotherapy was given in 104 patients (95%) with 83 patients (75%) receiving concurrently. One patient received induction crizotinib and one patient died before start of chemotherapy. With a median follow-up time of 15.3 months, the median overall survival was 31.2 months. Several genetic mutations were significantly associated with worse overall survival after therapy, including AKT2 any mutation (Hazard ratio 13.71, p<0.001), KMT2C truncating mutations (HR 13.42, p<0.001), KMT2D truncating mutations (HR 6.97, p<0.001), ARID1A frameshift mutations (HR 8.54, p<0.001), and FLT1 any mutation (HR 6.62, p<0.001). These genes were also associated with increased locoregional recurrence. Mutation in the PIK3C2G gene was significantly associated with improved overall survival. Association of other common genetic alterations such as EGFR mutation with response to therapy was not observed. Conclusion: This study coupled multiplex targeted sequencing with clinical outcome information to identify several potential genetic predictors of response to chemotherapy and radiation in locally advanced NSCLC. KMT2C and KMT2D encode two subunits of a histone methyltransferase, and mutations of KMD2 have been shown to correlate with worse survival in locally advanced and advanced NSCLC patients. Further studies including in vitro validations are necessary to confirm the findings. Background: V20 and MLD are the most commonly used dose constraints for radiation pneumonitis (RP) prediction. However, intensity-modulated radiation therapy (IMRT) has unrestricted beam arrangements, an infinite number of very different dose distributions could be generated in the lung volume outside the planning target volume (PTV). Conventional dose constraints from traditional 3D conformal RT may not be valid for IMRT treatment. We hypothesize that lung dosimetric parameters may have different RP predictive values from that of traditional constraints (largely generated from 3D treatment) in IMRT treated lung cancer patients. Method: We retrospectively enrolled184 IMRT treated lung cancer patients from January 2014 to October 2017. The primary endpoint was acute grade 2 or higher symptomatic radiation pneumonitis (RP2), based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.03). Vdose (from V5 to V50) and MLD were generated from the lung volume outside PTV. Univariate and multivariate logistic regression analysis was used to evaluate the association between the dose parameters outside PTV to RP2. We employed area under the curve (AUC) for the receiver operating characteristic curve (ROC) to assess prediction accuracy for the single or multi-variate model. Result: 26 out of 184 lung cancer patients (14.1%) developed RP2 within 3 months after the end of IMRT treatment. In univariate logistic regression, although none of the clinical parameters was significantly associated with RP2, female gender (P¼0.051) and chemotherapy (P¼0.151) had a trend of correlation. V5 (P¼0.007), V10(P¼0.012) V20 (P¼0.004), V30 (P¼0.003) and MLD (P¼0.004) were significantly associated with RP2 incidence. From ROC curve, the largest AUC of 0.67 was generated from V30, which showed a better predictive value compared with other dosimetric factors. Multivariate logistic regression analysis showed the only significant dosimetric factor is V30 (P¼0.021). Combining gender and chemotherapy factors, V30 has an AUC of 0.71 which is the largest among all the other dosimetric factors. Conclusion: For IMRT treated lung cancer patients, V30 generated from lung volume outside PTV may predict RP more accurately than traditional dosimetric parameters. Keywords: intensity-modulated radiation therapy (IMRT), Predict, Radiation pneumonitis ( Background: Despite lack of proven survival benefit, national guidelines recommend that patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation (CRT) using weekly regimens receive two additional cycles of full dose consolidation chemotherapy (cCT). We seek to explore the benefit of cCT in our mature annotated cohort of stage III NSCLC patients treated with modern radiation therapy (RT) and predominantly weekly carboplatin/paclitaxel-based CRT. Method: In this retrospective analysis, 355 consecutive patients with stage III NSCLC treated with either definitive CRT alone (bimodality) or followed by surgery (trimodality), between the years 2000-2013 were analyzed. Median age of the patients was 60 years (range: 30-86). Stage grouping was IIIA: 56.3%, T3/4: 49%, N2: 61.4%; N3: 21.4%. Histology was evenly distributed between squamous, adenocarcinoma, other or not specified. Concurrent CRT was delivered in 92.1% of the patients, 74% receiving weekly carboplatin/paclitaxel. Median radiation dose was 63Gy (range 10.8-81.6Gy). Data on cCT use was available in 304 patients, 69.7% receiving cCT. Logistic regression was performed to assess predictors for the use of cCT. Kaplan-Meier method and Cox proportional hazards model was used to estimate the overall (OS) and freedom-from-recurrence (FFR) adjusted for age, gender, marital status, insurance status, smoking history, COPD diagnosis, performance status, Charlson score, year of diagnosis, concurrent vs sequential CRT, RT technique, RT dose and surgery. Result: With a median follow up of 15 months (range: 1-184 months), OS (median/5-year) with and without cCT was 30.2 months/ 30.5% and 15.3 months/ 12.9%, respectively (multivariate adjusted HR for death: 0.50; 95% CI: 0.37-0.69, p < 0.001). Corresponding values for FFR were 19 months/ 27% and 11.2 months/ 11.4% (adjusted HR: 0.54; 95% CI: 0.37-0.77, p ¼ 0.001). On subset analysis, the OS benefit was seen in patients undergoing bimodality therapy (HR: 0.57; 95% CI: 0.40-0.83, p ¼ 0.003) but not for trimodality therapy (p ¼ 0.124). Similarly, an OS benefit was seen in stage IIIA (HR: 0.35; 95% CI: 0.23-0.55, p < 0.001) but not for stage IIIB patients (p ¼ 0.071). The only factor predicting the use of cCT was primary treatment: bimodality vs trimodality (OR: 2.2; 95% CI: 1.1-4.3, p ¼ 0.018 favoring bimodality). Conclusion: Consolidation chemotherapy should continue to be strongly considered for stage III NSCLC patients, especially those undergoing bimodality therapy receiving weekly sensitizing doses of carboplatin-paclitaxel and with stage IIIA disease. The relative benefit of cCT in the setting of maintenance durvalumab (or other immunotherapy) needs further evaluation. Keywords: consolidation chemotherapy, loco-regional NSCLC
